TCR2
TCR2 was a discovery-stage pharmaceutical company, founded in 2015 in Cambridge, MA, that developed a proprietary TRuC™ T-cell receptor fusion construct platform for engineered cell therapy. The company was publicly listed on NASDAQ (TCRR), raised approximately $297M in funding, and is no longer operating as an independent entity.
- Company typePrivate
- Founded2015
- HeadquartersCambridge, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
What TCR2 does
TCR2 was a discovery-stage pharmaceutical company founded in 2015 and headquartered in Cambridge, Massachusetts, United States. The company developed a proprietary TRuC™ (T cell receptor fusion construct) platform, an engineered T-cell therapy framework intended to direct immune cells against cancer targets. TCR2 operated as a publicly listed entity on NASDAQ under the ticker symbol TCRR, with a headcount range of 101–250 employees. Historically, the company attracted substantial capital from the biotech investor ecosystem, raising approximately $297.3 million across four funding rounds between 2016 and 2020, with notable participation from MPM Capital, 6 Dimensions Capital, Hillhouse Investment, Redmile Group, and UBS Asset Management, among others. The company's leadership included founder Patrick Baeuerle and chairman Ansbert Gadicke, supported by a Chief Business and Strategy Officer (Rosemary Harrison) and a Chief IP Counsel (Greg Sieczkiewicz).
As a clinical-stage cell therapy developer, TCR2's business model was oriented toward long-cycle biotech value creation: raise capital, advance the TRuC™ pipeline through preclinical and clinical milestones, and ultimately exit via either a commercial launch, partnership, or acquisition. The company had no disclosed commercial products, pricing, or revenue model, consistent with its pre-commercial stage. The addressable market was the engineered cell therapy / CAR-T adjacent space, where third-party market sizing estimates projected the market reaching $85.61 billion by 2030 (45.31% CAGR from 2022), $196.21 billion by 2035 (34.27% CAGR from 2025), or $616.91 billion by 2034 (32.96% CAGR from 2025), with North America holding the dominant share.
Critically, the present data indicates TCR2 no longer operates as an active standalone entity. The company's primary corporate domain (tcr2.com) is currently parked on GoDaddy with no active website content, and subsequent source blocks note the absence of revenue, products, management information, operating status, or parent/subsidiary structure. This combination of signals — a past-tense product description, no operational data, and a dormant web presence — is consistent with corporate dissolution, asset sale, or acquisition, though no explicit confirmation of such an event is contained in the provided input.
TCR2 firmographics
Firmographics- Name
- TCR2
- Website
- https://tcr2.com
- Company type
- Private
- Founded year
- 2015
- Headcount range
- 101–250 employees
- Short description
- TCR2 was a discovery-stage pharmaceutical company, founded in 2015 in Cambridge, MA, that developed a proprietary TRuC™ T-cell receptor fusion construct platform for engineered cell therapy. The company was publicly listed on NASDAQ (TCRR), raised approximately $297M in funding, and is no longer operating as an independent entity.
- Ownership category
- akta.pro rank
TCR2 industry classification
Industry- Product category
- Cancer Cell Therapy
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- CAR-T & TCR-T Therapies (HLAAABAC)
Keywords
Where TCR2 is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Markets served
TCR2 business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
TCR2 product offering
Product offeringCore offering
TCR2 is a discovery-stage pharmaceutical company developing T cell receptor-based immunotherapies using its proprietary TRuC™ (T Cell Receptor Fusion Construct) platform. The company engineers T cells to recognize and kill cancer cells, with a pipeline targeting solid tumors and hematological malignancies. TCR2 is publicly traded on NASDAQ under the symbol TCRR.
Product overview
No product or service information is available for TCR2. The company's domain (tcr2.com) is currently parked and listed for sale via GoDaddy, with no active website content describing the company's offerings, technology platform, or product portfolio.
Differentiator
Problem solved
Functional benefit
Products and services
- TRuC™ Platform
Companies that use TCR2
Customer profileIdeal customer profiles2 records
TCR2 technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
TCR2 partnerships and signals
Strategic signalScale indicators5 records
Recent moves5 records
Expansion highlights1 record
TCR2 competitors and assessment
Company assessmentDirect peers
- Adaptimmune: Adaptimmune develops engineered T-cell receptor therapies designed to recognize cancer targets. Its TCR-T focus and cell-therapy development model are closely comparable to TCR2's engineered T-cell approach.
- Immatics: Immatics develops TCR-based and TCR-bispecific cancer immunotherapies. It is comparable through its engineered T-cell receptor technology, oncology focus, and clinical-stage drug-development model.
- Gracell Biotechnologies: Gracell develops engineered autologous and allogeneic cell therapies using its FasTCAR and TruUCAR platforms. Its focus on next-generation T-cell manufacturing and therapeutic design is directly relevant to TCR2.
- Autolus Therapeutics: Autolus develops programmed CAR-T cell therapies for cancer. It is a direct product and business-model peer because both companies seek to create engineered T-cell therapies with improved tumor recognition and persistence.
- CARGO Therapeutics: CARGO Therapeutics develops engineered T-cell therapies, including CAR-T programs for hematologic malignancies and solid tumors. Its cell-therapy platform and oncology development pathway closely resemble TCR2's stated activities.
- Cellectis: Cellectis develops gene-edited allogeneic CAR-T cell therapies. It is comparable through its use of proprietary cell-engineering technology to develop targeted oncology therapies.
- Caribou Biosciences: Caribou develops genome-edited, off-the-shelf CAR-T cell therapies using CRISPR-based technology. Its allogeneic cell-therapy platform and oncology focus provide a relevant comparator for TCR2.
- Fate Therapeutics: Fate Therapeutics develops engineered immune-cell therapies derived from induced pluripotent stem cells. It is comparable in developing proprietary cellular engineering platforms intended to create scalable cancer therapies.
- CRISPR Therapeutics: CRISPR Therapeutics develops gene-edited cell therapies, including allogeneic CAR-T programs. Its platform-based approach to engineering therapeutic cells is comparable to TCR2's proprietary TRuC development model.
- Arcellx: Arcellx develops controllable CAR-T therapies for cancer using its proprietary binding-domain technology. It is a direct peer based on engineered autologous T-cell therapies, oncology targets, and clinical development.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat3 records
Key risks4 records
Key highlights5 records
Customer concentration
TCR2 social profiles
Digital presenceTCR2 financial estimates
Financial estimateRevenue estimate
Valuation estimate
TCR2 leadership team
Management profileNumber of profiles
Profiles4 records
TCR2 funding detail
Funding detailFunding overview
Funding rounds4 records
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TCR2 M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TCR2
What does TCR2 do?
TCR2 is a discovery-stage pharmaceutical company developing T cell receptor-based immunotherapies using its proprietary TRuC™ (T Cell Receptor Fusion Construct) platform. The company engineers T cells to recognize and kill cancer cells, with a pipeline targeting solid tumors and hematological malignancies. TCR2 is publicly traded on NASDAQ under the symbol TCRR.
When was TCR2 founded?
TCR2 was founded in 2015. It employs 101 to 250 people.
Where is TCR2 based?
TCR2 is headquartered in Cambridge, United States, in the North America region.
Who are TCR2's main competitors?
Direct peers on record are Adaptimmune, Immatics, Gracell Biotechnologies, Autolus Therapeutics, CARGO Therapeutics, Cellectis, Caribou Biosciences, Fate Therapeutics, CRISPR Therapeutics and Arcellx.
Does TCR2 have an API?
No public API is recorded for TCR2.
What industry is TCR2 in?
TCR2's product category is Cancer Cell Therapy. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies. Its NAICS code is 325412 and its SIC code is 2834.